{"id":126876,"date":"2026-07-12T17:40:32","date_gmt":"2026-07-12T17:40:32","guid":{"rendered":"https:\/\/www.europesays.com\/canada\/126876\/"},"modified":"2026-07-12T17:40:32","modified_gmt":"2026-07-12T17:40:32","slug":"bausch-healths-bhc-canadian-subsidiary-lists-prokedi-dosages-in-ramq-formulary","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/canada\/126876\/","title":{"rendered":"Bausch Health\u2019s (BHC) Canadian Subsidiary Lists PrOKEDI Dosages in RAMQ Formulary"},"content":{"rendered":"\n

Bausch Health Companies Inc. (NYSE:BHC<\/a>) is one of the 15 best NYSE penny stocks to buy according to hedge funds<\/a>. <\/p>\n

On July 6, Bausch Health Companies Inc.’s (NYSE:BHC) subsidiary, Bausch Health Canada, shared the listing of PrOKEDI’s 75mg and 100mg dosages in the R\u00e9gie de l’assurance maladie du Qu\u00e9bec (RAMQ) formulary. <\/p>\n

<\/a> <\/p>\n

PrOKEDI is an injectable suspension of risperidone that is used to treat adults with schizophrenia. It attains clinically meaningful concentrations of the active compound in the initial several hours after injection, without the need for oral supplementation or a loading dose. It also offers prolonged drug release throughout a four-week dosing interval. <\/p>\n

According to Bausch Health, this decision by the company signifies a major milestone in obtaining reimbursement for PrOKEDI in Quebec. The company noted that it will maintain its efforts with other provincial jurisdictions consistent with their respective coverage processes. <\/p>\n

Back on June 9, Bausch Health Canada disclosed that it had completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), which led to a Letter of Intent for PrOKEDI’s 100mg and 75mg dosages. Bausch Health Canada’s General Manager, Amy Cairns, noted that this development will enable the company to increase access to PrOKEDI through public drug programs. She further stated: <\/p>\n

“This milestone brings us closer to supporting patients, their families, and caregivers with new treatment options, and we look forward to quickly finalizing agreements so Canadians can benefit as soon as possible.” <\/p>\n

Bausch Health Companies Inc. (NYSE:BHC) engages in the development and sale of a range of items for the healthcare industry. The company specializes in different areas, including hepatology, neurology, dermatology, gastroenterology, generic pharmaceuticals, over-the-counter items, aesthetic medical devices, and eye health. <\/p>\n

While we acknowledge the potential of BHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0<\/a>best short-term AI stock<\/a>. <\/p>\n

READ NEXT:\u00a033 Stocks That Should Double in 3 Years<\/a> and 15 Stocks That Will Make You Rich in 10 Years<\/a>. <\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"Bausch Health Companies Inc. (NYSE:BHC) is one of the 15 best NYSE penny stocks to buy according to…\n","protected":false},"author":2,"featured_media":126877,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[42386,17,7833,42387],"class_list":["post-126876","post","type-post","status-publish","format-standard","has-post-thumbnail","category-canada","tag-bausch-health-companies-inc","tag-canada","tag-nyse","tag-regie-de-lassurance-maladie-du-quebec"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/posts\/126876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/comments?post=126876"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/posts\/126876\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/media\/126877"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/media?parent=126876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/categories?post=126876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/tags?post=126876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}